Arcturus Therapeutics

Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit

Retrieved on:

수요일, 4월 28, 2021

Lung disorders, Anatomy, Medical specialties, Companies, Sanofi, Channelopathies, Cystic fibrosis, Pulmonology, Respiratory disease, Lung, Bronchiectasis, Arcturus Therapeutics

Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial.

Key Points:

Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial.
Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform.
Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver.
Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting

Retrieved on:

화요일, 4월 27, 2021

RNA, Lipids, Solid lipid nanoparticle, Gene editing, Guide RNA, Genome editing, Arcturus Therapeutics, RNA, Lipids, Solid lipid nanoparticle, Gene editing, Guide RNA, Genome editing, Arcturus Therapeutics

b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021.

Key Points:

b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021.
For this study, Beam evaluated editing levels in the liver of non-human primates using a lipid nanoparticle (LNP) delivery system containing a novel adenine base editor (ABE) and reporter sgRNA.
To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities.
This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

MRNA Vaccines and Therapeutics Market size is Projected to reach USD 2911.9 million 2026, Says Brandessence Market Research

Retrieved on:

월요일, 4월 5, 2021

Branches of biology, Life sciences, Biology, Medical research, Vaccination, RNA, RNA vaccine, Vaccine, Messenger RNA, Arcturus Therapeutics, RNA therapeutics

Global mRNA Vaccines & Therapeutics Market: Market Player Analysis

Key Points:

Global mRNA Vaccines & Therapeutics Market: Market Player Analysis
On the basis of type global mRNA Vaccines & Therapeutics market is segmented into Standardization of Cancer Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine and Infection Prevention mRNA Vaccine.
Standardized Therapeutic Cancer mRNA Vaccines is dominating the type segment in mRNA Vaccines & Therapeutics market with revenue of USD 232.1 million in 2019 and is expected to reach USD 1161.8 million in 2026 with estimated CAGR of 28.70%.
Global mRNA Vaccines & Therapeutics Market: By Type
Global mRNA Vaccines & Therapeutics Market: By End Users
On the basis of end user, global mRNA Vaccines & Therapeutics market is segmented into infectious diseases, cancer and others.
Brandessence Market Research & Consulting Pvt ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts.

MRNA Vaccines and Therapeutics Market size is Projected to reach USD 2911.9 million 2026, Says Brandessence Market Research

Retrieved on:

월요일, 4월 5, 2021

Branches of biology, Life sciences, Biology, Medical research, Vaccination, RNA, RNA vaccine, Vaccine, Messenger RNA, Arcturus Therapeutics, RNA therapeutics

Global mRNA Vaccines & Therapeutics Market: Market Player Analysis

Key Points:

Global mRNA Vaccines & Therapeutics Market: Market Player Analysis
On the basis of type global mRNA Vaccines & Therapeutics market is segmented into Standardization of Cancer Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine and Infection Prevention mRNA Vaccine.
Standardized Therapeutic Cancer mRNA Vaccines is dominating the type segment in mRNA Vaccines & Therapeutics market with revenue of USD 232.1 million in 2019 and is expected to reach USD 1161.8 million in 2026 with estimated CAGR of 28.70%.
Global mRNA Vaccines & Therapeutics Market: By Type
Global mRNA Vaccines & Therapeutics Market: By End Users
On the basis of end user, global mRNA Vaccines & Therapeutics market is segmented into infectious diseases, cancer and others.
Brandessence Market Research & Consulting Pvt ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts.

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Retrieved on:

화요일, 3월 30, 2021

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Key Points:

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
Arcturus technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer

Retrieved on:

화요일, 3월 30, 2021

Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Biology, Life sciences, Biotechnology, Bioethics, Gene therapy, Molecular biology, Rare disease, Vertex Pharmaceuticals, Arcturus Therapeutics

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.

Key Points:

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.
A neurologist and neuroscientist, Dr. Wright brings to AavantiBio more than 20 years of medical research and drug development experience in specialty and CNS orphan diseases, including cystic fibrosis, dementias, epilepsy, mitochondrial diseases, and sickle cell disease.
An accomplished scientific and medical leader in both the academic and biopharmaceutical communities, Dr. Wright most recently served as Senior Vice President and Chief Medical Officer of Cyclerion Therapeutics (NASDAQ: CYCN), where he led global development functions across therapeutic areas, including clinical development and operations, regulatory affairs, patient safety, quality, and pharmaceutical development.
Earlier this month, AavantiBio announced the appointments of Douglas J. Swirsky as Chief Financial Officer and Treasurer, and Ty Howton as Chief Operating Officer and General Counsel.

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

Retrieved on:

월요일, 3월 15, 2021

Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Branches of biology, Hepatic stellate cell, Solid lipid nanoparticle, Liver, LNP, Biology, Arcturus Therapeutics

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.

Key Points:

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.
As longstanding leaders in nucleic acid delivery, Genevant has developed a novel hepatic stellate cell-directed LNP platform to meet this challenge and we are delighted to partner with Takeda to utilize this innovation to develop new treatments for patients suffering from liver fibrosis.
Takeda has exclusive rights to Genevants LNP technology for a specified number of selected hepatic stellate cells targets.
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development.

Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights

Retrieved on:

목요일, 3월 11, 2021

Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Life sciences, Arcturus Therapeutics, Companies, Biotechnology

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported business highlights and financial results for the year ended December 31, 2020.

Key Points:

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported business highlights and financial results for the year ended December 31, 2020.
ET today to discuss its full-year 2020 financial results.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results.

Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors

Retrieved on:

화요일, 3월 9, 2021

Biotechnology, Pharmaceutical, Genetics, Health, Articles, Arcturus Therapeutics, Sassine, Board of directors, Business

and Mr. Andrew Sassine to its Board of Directors.

Key Points:

and Mr. Andrew Sassine to its Board of Directors.
Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs.
Andrew Sassine currently serves as Chief Financial Officer and member of the board of directors of Arcturus Therapeutics.
I am excited to join the Exicure team and its distinguished Board of Directors, said Andrew Sassine.

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

Retrieved on:

월요일, 3월 8, 2021

Life sciences, Biotechnology, Biology, Ultragenyx, RNA, Arcturus Therapeutics, Biopharmaceutical, Messenger RNA

Ultragenyx is developing UX053 and a number of other mRNA therapies in the preclinical stage for undisclosed indications.

Key Points:

Ultragenyx is developing UX053 and a number of other mRNA therapies in the preclinical stage for undisclosed indications.
These mRNA therapies come out of a long-term collaboration with Arcturus Therapeutics, a clinical-stage messenger RNA medicines company.
Part 1 is open label and will enroll up to 12 patients who receive a single ascending dose of UX053.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.